Background and aimsThe pathological core of rheumatoid arthritis (RA) is progressive bone destruction driven by chronic inflammation. The Wnt/β-catenin signaling pathway plays a key regulatory role in bone metabolism, but it is disrupted by the inflammatory environment in RA.
This study investigates the mechanism by which moxibustion combined with conventional Western medicine modulates the Wnt/β-catenin signaling pathway to coordinate inflammation and bone metabolism in rheumatoid arthritis (RA).MethodsThis study randomly assigned 70 patients to a moxibustion group (n=35) and a control group (n=35). The control group received oral methotrexate (10 mg/week) combined with folic acid (10 mg/week).
The moxibustion group received the same medication as the control group plus moxibustion therapy primarily targeting Zusanli (ST36), and Ashi points, administered three times weekly for a 4-week course.
Frontiers in Immunology published a clinical update in Infectious Disease on 22 May 2026.
The item focuses on Mechanistic study on the reduction of TNF-α and β-CTX levels in RA patients by moxibustion combined with western medication through regulation of the Wnt/β-catenin pathway.
Review the original article for the full source wording and details.